Objective: To evaluate and compare patient and physician preferences for the benefits and risks of currently available adjuvant melanoma treatments. Methods: Patients with stage II/III melanoma and oncologists in the USA were recruited from 6 clinical sites and an online panel to complete a survey. Preferences were assessed using a paired comparison discrete choice experiment that allowed for opt-out ( i.e. no treatment). The treatments comprised 7 attributes, each with 3 levels associated with pegylated interferon, high-dose interferon, and ipilimumab. Attributes included efficacy outcomes, dosing regimen, and risks of moderate to severe toxicities. In addition, open-ended maximum acceptable risk (MAR) questions assessed tradeoffs between toxicity risk and efficacy. Results: 142 patients (45 stage II; 97 stage III) chose a treatment in 78% of the choice tasks, while physicians ( N = 127) chose treatment 79% of the time. The rankings of relative attribute importance were concordant between the patients and physicians for the top 4: 10-year survival in metastatic melanoma, fatigue risk, 3-year recurrence-free survival (RFS), and depression risk. Patients and physicians valued the difference in 21% survival versus no survival benefit about 3 and 4 times as much, respectively, as reducing diarrhea risk from 41% to 1% or reducing depression risk from 40% to 1%. The MAR of severe diarrhea and of a life-threatening event increased as the chance of 3-year RFS increased, with patients reporting higher risks than physicians. Conclusion: Patients and physicians were concordant in their preferences in adjuvant melanoma, preferring treatment versus none and judging potential efficacy to outweigh risks of toxicities.
Garbe, C., Peris, K., Hauschild, A., et al. (2012) Diagnosis and Treatment of Melanoma. European Consensus-Based Interdisciplinary Guideline-Update 2012. European Journal of Cancer, 48, 2375-2390. https://doi.org/10.1016/j.ejca.2012.06.013
American Cancer Society. Key Statistics for Melanoma Skin Cancer. 2016. http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer- key-statistics
American Cancer Society. Cancer Facts and Figures 2009. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/
Grob, J.J., Jouary, T., Dréno, B., et al. (2013) Adjuvant Therapy with Pegylated Interferon Alfa-2b (36 Months) versus Low-Dose Interferon Alfa-2b (18 Months) in Melanoma Patients without Macrometastatic Nodes: An Open-Label, Randomised, Phase 3 European Association for Dermato-Oncology (EADO) Study. European Journal of Cancer, 49, 166-174. https://doi.org/10.1016/j.ejca.2012.07.018
McMasters, K.M., Egger, M.E., Edwards, M.J., et al. (2016) Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. Journal of Clinical Oncology, 34, 1079-1086. https://doi.org/10.1200/JCO.2015.63.3776
Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., et al. (2015) Adjuvant Ipilimumab versus Placebo after Complete Resection of High-Risk Stage III Melanoma (EORTC 18071): A Randomised, Double-Blind, Phase 3 Trial. The Lancet Oncology, 16, 522-530. https://doi.org/10.1016/S1470-2045(15)70122-1
Albrecht, K.J., Nashan, D., Meiss, F., Bengel, J. and Reuter, K. (2014) Shared Decision Making in Dermato-Oncology: Preference for Involvement of Melanoma Patients. Melanoma Research, 24, 68-74. https://doi.org/10.1097/CMR.0000000000000030
Schofield, P.E., Beeney, L.J., Thompson, J.F., Butow, P.N., Tattersall, M.H. and Dunn, S.M. (2001) Hearing the Bad News of a Cancer Diagnosis: The Australian Melanoma Patient’s Perspective. Annals of Oncology, 12, 365-371. https://doi.org/10.1023/A:1011100524076
Kilbridge, K.L., Weeks, J.C., Sober, A.J., et al. (2001) Patient Preferences for Adjuvant Interferon Alfa-2b Treatment. Journal of Clinical Oncology, 19, 812-823.
Krammer, R. and Heinzerling, L. (2014) Therapy Preferences in Melanoma Treatment— Willingness to Pay and Preference of Quality versus Length of Life of Patients, Physicians and Healthy Controls. PLoS ONE, 9, e111237. https://doi.org/10.1371/journal.pone.0111237
US Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health and Center for Biologics Evaluation and Research (2016) Patient Preference Information—Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and de Novo Requests, and Inclusion in Decision Summaries and Device Labeling. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. http://www.fda.gov/downloads/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/ UCM446680.pdf
Bridges, J.F.P., Kinter, E.T., Kidane, L., Heinzen, R.R. and McCormick, C. (2008) Things are Looking up since We Started Listening to Patients: Recent Trends in the Application of Conjoint Analysis in Health 1970-2007. Patient, 1, 273-282. https://doi.org/10.2165/1312067-200801040-00009
Bridges, J.F.P., Hauber, A.B., Marshall, D., et al. (2011) Conjoint Analysis Applications in Health—A Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value in Health, 14, 403-413. https://doi.org/10.1016/j.jval.2010.11.013
Wong, S.F., Norman, R., Dunning, T.L., Ashley, D.M. and Lorgelly, P.K. (2014) A Protocol for a Discrete Choice Experiment: Understanding Preferences of Patients with Cancer towards Their Cancer Care Across Metropolitan and Rural Regions in Australia. BMJ Open, 4, e006661. https://doi.org/10.1136/bmjopen-2014-006661
US Department of Health and Human Services, National Institutes of Health and National Cancer Institute (2009) Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
Kirkwood, J.M., Strawderman, M.H., Ernstoff, M.S., Smith, T.J., Borden, E.C. and Blum, R.H. (1996) Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. Journal of Clinical Oncology, 14, 7-17.
Sylatron (Peginterferon Alfa-2b) Prescribing Information (2011) Schering Corporation, Kenilworth. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103949s5153lbl.pdf
Intron A (Interferon Alfa-2b) Prescribing Information (2016) Merck Sharp & Dohme Corp, Whitehouse Station. https://www.merck.com/product/usa/pi_circulars/i/intron_a/intron_a_pi.pdf
Yervoy (Ipilimunab) Prescribing Information (2016) Bristol-Myers Squibb, Princeton. http://packageinserts.bms.com/pi/pi_yervoy.pdf
Schadendorf, D., Hodi, F.S., Robert, C., et al. (2015) Pooled Analysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 33, 1889-1894. https://doi.org/10.1200/JCO.2014.56.2736
O’Donnell, H., Phillips, R.S., Wenger, N., Teno, J., Davis, R.B. and Hamel, M.B. (2003) Preferences for Cardiopulmonary Resuscitation among Patients 80 Years or Older: The Views of Patients and Their Physicians. Journal of the American Medical Directors Association, 4, 139-144. https://doi.org/10.1016/S1525-8610(04)70323-0
Johnson, F.R., Lancsar, E., Marshall, D., et al. (2013) Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. ISPOR Task Force Report. Value in Health, 16, 3-13. https://doi.org/10.1016/j.jval.2012.08.2223
Hauber, A.B., Fairchild, A.O. and Johnson, F.R. (2013) Quantifying Benefit-Risk Preferences for Medical Interventions: An Overview of a Growing Empirical Literature. Applied Health Economics and Health Policy, 11, 319-329. https://doi.org/10.1007/s40258-013-0028-y
Hauber, A.B., González, J.M., Groothuis-Oudshoorn, C.G.M., et al. (2016) Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value in Health, 19, 300-315. https://doi.org/10.1016/j.jval.2016.04.004
Hamelinck, V.C., Bastiaannet, E., Pieterse, A.H., et al. (2014) Patients’ Preferences for Surgical and Adjuvant Systematic Treatment in Early Breast Cancer: A Systematic Review. Cancer Treatment Reviews, 40, 1005-1018. https://doi.org/10.1016/j.ctrv.2014.06.007
Brundage, M.D., Davidson, J.R., Mackillop, W.J., Feldman-Stewart, D. and Groome, P. (1998) Using a Treatment-tradeoff Method to Elicit Preferences for the Treatment of Locally Advanced Non-Small-Cell Lung Cancer. Medical Decision Making, 18, 256-267. https://doi.org/10.1177/0272989X9801800302
Chandwani, S., Stevinson, K.L. and Mehnert, J.M. (2014) Predictors of Receipt of Immunotherapy for Stage II and III Melanoma in United States Clinical Practice. Journal of Clinical Oncology, 32, e20003.
Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., et al. (2016) Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine, 375, 1845-1855. https://doi.org/10.1056/NEJMoa1611299